Deltavasc misses Phase II endpoint

Valentis (VLTS) was off $4.29 (65%) to $2.36 on 9.7 million shares on Wednesday after its Deltavasc did not meet the primary endpoint in a double-blind Phase II trial in 100 patients with peripheral arterial disease (PAD). Patients receiving Deltavasc plus PINC polymer failed to show a significant improvement in exercise tolerance compared to patients given the polymer alone, which served as the control. In both groups, exercise tolerance significantly increased from baseline. ...